Clarus Leads $60M Biolex Deal

Xconomy Boston — 

Cambridge, MA-based Clarus Ventures led a $60 million Series D financing for Biolex Therapeutics, according to an announcement from the Pittsboro, NC-based startup. The deal was joined by new investor OrbiMed Advisors and existing investors including Intersouth Partners, Quaker BioVentures, Johnson & Johnson Development Corporation, Investor Growth Capital, Polaris Ventures, Mitsui & Company, The Dow Chemical Company, JP Morgan Securities, and the North Carolina Economic Development Fund. Biolex plans to use the cash to ready its lead drug candidate, a controlled-release version of interferon alfa for the treatment of hepatitis C, for Phase 3 clinical trials.